Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Maria Lacarra"'
Autor:
Vivian Brache, Harold A. Nash, Pekka Lähteenmäki, Edith Weisberg, Daniel R. Mishell, Maria Lacarra, Kaisa Elomaa, Francisco J. Alvarez, Ian S. Fraser
Publikováno v:
Contraception. 61:131-138
Vaginal inspections using colposcopy before insertion of contraceptive vaginal rings and at 2-month intervals during ring use were conducted on 169 users of four different formulations. The rings studied released Nestorone alone (50, 75, 100 g daily
Autor:
Francisco Alvarez, Maria Lacarra, Irving Sivin, Vivian Brache, Janet Stern, Cynthia Klaisle, Daniel R. Mishell, Philip D. Darney, Livia Wan
Publikováno v:
Contraception. 58:275-282
A 5-year trial of a two-rod contraceptive implant, which releases the progestin levonorgestrel (LNG rod), was conducted at four clinics with 594 women. Mean age and weight at admission were 25.5 years and 62.4 kg, respectively. Consent to continue th
Autor:
Sven-Eric Olsson, Janet Stern, Vivian Brache, Irving Sivin, Viveca Odlind, Maria Lacarra, Philip D. Darney, Margarita Pavez, Pentti Holma, Terence McCarthy, Daniel R. Mishell, Cynthia Klaisle, Soledad Diaz, Francisco J. Alvarez
Publikováno v:
American Journal of Obstetrics and Gynecology. 166:1208-1213
The objectives were to measure rates of planned pregnancy and factors affecting these rates after use of very-long-acting contraceptive methods (Norplant or Norplant II implants, a levonorgestrel-releasing intrauterine contraceptive device, or the co
Publikováno v:
Fertility and Sterility. 55:766-770
Daily transvaginal ultrasound (US) scanning of the ovaries to assess follicular development and daily blood sampling were performed on 19 Norplant (Leiras, Turku, Finland) subdermal contraceptive implant users who had regular menstrual cycles and on
Autor:
Rebeca Massai, A.M. Salvatierra, Francisco Alvarez, Maria Lacarra, Vivian Brache, Daniel R. Mishell, Christopher Elias, Christiana Coggins, David M. Phillips, Pekka Lähteenmäkl, Ian S. Fraser
Publikováno v:
Contraception. 56:387-389
There is an urgent need to develop safe, effective, and acceptable vaginal products for the prevention of sexually transmitted infections. Preliminary in vitro results suggest that vaginal formulations of sulfated polysaccharides, including iota-carr
Publikováno v:
Obstetrical & Gynecological Survey. 50:605-607
The acceptability of a vaginal ring releasing ethinyl oestradiol 20 mcg per day and norethindrone acetate 1 mg per day was assessed during a six-month phase II trial comparing three different regimens, which was carried out simultaneously in Los Ange
Autor:
Vivian Brache, Ian S. Fraser, Maria Lacarra, Edith Weisberg, Harold A. Nash, Daniel R. Mishell, Francisco J. Alvarez
Publikováno v:
Contraception. 59(5)
A combined contraceptive vaginal ring designed to last 12 months was tested at three clinic sites. This ring released approximately 1 mg of norethindrone acetate (NET-Ac) and 20 micrograms of ethinyl estradiol (EE) daily. A total of 60 women were enr
Autor:
Edith Weisberg, Ian S. Fraser, Maria Lacarra, Daniel R. Mishell, Theodore M. Jackanicz, Phillip Darney
Publikováno v:
Contraception. 59(5)
Two combined contraceptive vaginal rings (CVR) each releasing approximately 1 mg norethindrone acetate (NET-Ac) and either 20 micrograms or 15 micrograms ethinyl estradiol over 24 h were tested at three clinic sites in Los Angeles, San Francisco, and
Publikováno v:
Contraception. 58(1)
A study was undertaken to determine whether ingestion of the selective estrogen receptor modulator tamoxifen followed by vaginal administration of the prostaglandin misoprostol would be an effective medical method of elective termination of early pre
Effect of different insertion regimens on side effects with a combination contraceptive vaginal ring
Publikováno v:
Contraception. 56(4)
The study population included 159 women aged 18 to 37 years requiring contraception (60 in Sydney, 99 in Los Angeles). The design consisted of a 6 month study of a contraceptive vaginal ring (CVR) releasing 20 micrograms ethinyl estradiol and 1 mg of